期刊文献+

CYP4F2基因单核苷酸多态性与日本高血压的相关性研究 被引量:2

Association between the SNPs of human CYP4F2 gene and essential hypertension in Japan
暂未订购
导出
摘要 目的:研究在不同性别中,CYP4F2基因单核苷酸多态性与日本高血压的关系。方法:249例日本原发性高血压患者和207例年龄匹配的对照(日本人)分别分为整体组、男性组、女性组。选择CYPF2基因的5个SNPs(rs3093105、rs3093135、rs1558139、rs2108622、rs3093200),应用TaqManSNP基因分型的方法进行基因分型,分析CYP4F2基因单核苷酸多态性与高血压的相关性。结果:高血压患者和对照相比较,rs1558139基因型的显性模式分布(CCversusCT+TT)在整体组和男性组中显著不同(P=0.037,P=0.005),高血压患者的CC基因型频率显著高于对照的CC基因型频率。Logistic回归分析显示,在剔除高血压主要危险因素的干扰后,男性组rs1558139的CC基因型分布在高血压患者和对照之间仍然保持差异(P=0.026),而整体组高血压患者和对照之间CC基因型分布的差异消失(P=0.247)。对于男性,高血压组的C等位基因频率显著高于对照组(P=0.025)。结论:CYP4F2基因rs1558139的CC基因型和C等位基因可做为日本男性高血压的基因标记。 Objective:The aim of the present study was to assess the association between the human CYP4F2 gene and essential hypartension(EH)in Japanese,using a case-control study that included a separate analysis of the gender groups.Methods:There were 249 EH patients and 238 age-matched controls genotyped for 5 SNPs of the human CYP4F2 gene(rs3093105,rs3093135,rs1558139,rs2108622,rs3093200).The data were assessed for 3 separate groups:the total subjects,men and women.Results:For the total and men subjects,the distribution of the dominant model of rs1558139(CC versus CT+ TT)differed significantly between the EH patients and control subjects(P=0.037,P=0.005,respectively),the CC genotype was higher in the EH patients than in the control subjects.Logistic regression showed that for the men,the CC genotype of rs1558139 keep higher in EH patients than in the control subjects(P=0.026),while for the total,the difference was disappeared(P=0.247).For men subjects,C allele is significantly higher in EH patients than the control subjects(P=0.025).Conclusions:In conclusion,the CC genotype and C allele of rs1558139 can be genetic marker of EH in Japanese men.
出处 《新疆医科大学学报》 CAS 2008年第9期1123-1127,共5页 Journal of Xinjiang Medical University
关键词 CYP4F2 单核苷酸多态性 高血压 CYP4F2 single nucleotide polymorphism hypertension
  • 相关文献

参考文献11

  • 1Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function [J]. Physiol Rev, 2002, 82:131-185.
  • 2Stec DE, Roman RJ, Flasch A, et al. Functional polymorphism in human CYP4F2 decreases 20-HETE production[J]. Physiol Genomics, 2007, 30:74-81.
  • 3Gainer JV, Bellamine A, Dawson EP, et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension[J]. Circulation, 2005, 111,63-69.
  • 4King LM, Gainer JV, David GL, et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension[J]. Pharmacogenet Genomics, 2005, 15:7-13.
  • 5Yu BN, Luo CH, Wang D, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls[J]. Clin Chim Acta, 2004, 348:57-61.
  • 6Kivisto KT, Niemi M, Schaeffeler E, et al. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study[J]. Am J Pharmacogenomics, 2005, 5:191-195.
  • 7Iwai N, Katsuya T, Ishikawa K, et al. Human prostacyclin synthase gene and hypertension: the suita stucty[J]. Circulation, 1999, 100:2231-2236.
  • 8Sookoian S, Gianotti TF, Gonzalez CD, et al. Association of the C-344T aldosterone synthase gene variant with essential hypertension: a meta analysis[J]. J Hypertens, 2007, 25:5-13.
  • 9McGiff JC, Quilley J. 20 Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure [J]. Curr Opin Nephrol Hypertens, 2001, 10:231-237.
  • 10Holla VR, Adas F, Imig JD, et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension[J]. Proc Natl Acad Sci USA, 2001, 98:5211-5216.

同被引文献21

  • 1BORGIANI P,CICCACCI C,FORTE V,et al.CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population[J].Pharmacogenomics,2009,10(2):261-266.
  • 2DENG S,ZHU G,LIU F,et al.CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population[J].Prog Neuropsychopharmacol Biol Psychiatry,2010,34(4):664-668.
  • 3SCONCE E A,KHAN T I,WYNNE H A,et al.The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen[J].Blood,2005,106(7):2329-2333.
  • 4WADELIUS M,CHEN L Y,ERIKSSON N,et al.Association of warfarin dose with genes involved in its action and metabolism[J].Hum Genet,2007,121(1):23-34.
  • 5PEREZ ANDREU V,ROLDAN V,ANTON A I,et al.Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy[J].Blood,2009,113(20):4977-4979.
  • 6SINGH O,SANDANARAJ E,SUBRAMANIAN K,et al.Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients[J].Drug Metab Pharmacokinet,2011,26(2):130-136.
  • 7FAVA C,MONTAGNANA M,ALMGREN P,et al.The V433M variant of the CYP4F2 is associated with ischemic stroke in male swedes beyond its effect on blood pressure[J].Hypertension,2008,52 (2):373-380.
  • 8MCDONALD M G,RIEDER M J,NAKANO M,et al.CYP4F2 is a vitamin K1 oxidase:An explanation for altered warfarin dose in carriers of the V433M variant[J].Mol Pharmacol,2009,75(6):1337-1346.
  • 9苏州大学,苏州旷远生物分子技术有限公司.一种用于华法林个体化用药相关基因SNP位点检测的试剂盒及其PCR扩增方法.中国,201010234597.8[P] 2010-12-01.
  • 10CALDWELL M D,AWAD T,JOHNSON J A,et al.CYP4F2 genetic variant alters required warfarin dose[J].Blood,2008,111(8):4106-4112.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部